status, and metastatic disease were identified as independent prognostic factors. Conclusion: Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.
Introduction
Pancreatic cancer remains one of the major unresolved health problems. First, the incidence and mortality of pancreatic cancer patients have increased. Worldwide, 302,464 patients died of pancreatic cancer in 2011 [1] . Deaths from pancreatic cancer in 2030 are projected to increase to 456,862 patients [2] . Second, the prognosis of pancreatic cancer has been still poor, and the 5-year survival has been reported less than 10% for last 30 years [3] . Especially, approximately 50% of the patients come to clinical attention with the metastatic disease, and their 5-year survival has been less than 3%.
For unresectable pancreatic cancer, gemcitabine had been used as a first-line agent from the second half of the 1990s to the 2000s. The median survival time (MST) in patients with the metastatic disease who were treated with gemcitabine alone or gemcitabine-based combination chemotherapy has been reported to be 6-7 months [4] .ing of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) has shown significant effects on overall survival compared with gemcitabine monotherapy [5] . However, because of the severe toxicity of FOLFIRINOX, it cannot be applied to all patients with unresectable pancreatic cancer [6] . At present, the choice of regimen, whether FOLFIRINOX or gemcitabine-based chemotherapy, depends on general conditions in each patient. As prognostic factors for unresectable pancreatic cancer, tumor factors such as serum carbohydrate antigen (CA) 19-9 level and tumor stage, and host factors including performance status, serum C-reactive protein level, and neutrophil-lymphocyte ratio have been reported to be associated with patients' survival [7] [8] [9] [10] . But, predicting the prognosis is not always easy, and markers reflecting the grade of spontaneous immune response to autologous cancer cells in vivo have not been elucidated yet.
Recently, we reported the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of human pancreatic cancer AsPC-1 cells and Panc-1 cells via down-regulation of Wnt/β-Catenin signaling pathway [11] . RPL29 is expressed on the surface of cells and takes part in cell-cell and cell-extracellular matrix adhesion [12, 13] . The expression of RPL29 is upregulated in various types of cancers including endometrial cancer [12] , hepatocellular carcinoma [14] , ovarian cancer [15] , and colon cancer [16] . The upregulation of RPL29 is associated with tumor growth and local invasion [16] . Depletion of RPL29 reduces tumor angiogenesis [17] , induces cell cycle arrest at G0/G1 phase [18] and cellular differentiation [19] , and promotes apoptosis [12] . Thus, the presence of serum anti-RPL29 may affect the prognosis of pancreatic cancer.
In this study, we measured serum anti-RPL29 levels and estimated the association of serum anti-RPL29 levels with clinical features in patients with unresectable pancreatic cancer.
Methods

Ethics
This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board at Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. Serum samples and data were collected after each subject provided written informed consent from March 2003.
Patients
We retrospectively reviewed 107 patients with unresectable adenocarcinoma of the pancreas, who were admitted to the Okayama University Hospital between March 2003 and December 2012. A diagnosis of pancreatic adenocarcinoma was confirmed by histological or cytological examination. All patients had no prior chemotherapy or radiotherapy. Of the 107 patients, two were transferred to other hospitals without followup, and were excluded from the present analysis. Thus, 105 patients were included in the present analysis. Clinical characteristics of the study population at the initiation of chemotherapy were shown in table 1 . Thirty-five (33%) patients were female, and median age was 64 (range, 38-85). Forty-one (39%) patients had locally advanced disease, and the remaining sixty-four (61%) had metastatic disease.
At the initiation of chemotherapy, the patient's complete medical history and physical examination, Eastern Cooperative Oncology Group performance status [20] , complete blood cell count, standard biochemical profile, electrocardiogram, chest X-rays, and computed tomography scans of the chest and upper and lower abdomen were evaluated. Tumors were staged according to the sixth edition of the tumor node metastasis (TNM) classification of the International Union against Cancer (UICC) [21] . Modified Glasgow prognostic score, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio were evaluated as previously described [9] .
Serum samples at the initiation of chemotherapy were obtained from 105 patients with unresectable pancreatic cancer. Moreover, serum samples from 62 healthy volunteers (controls) were collected. Collected serum samples were stored -30 ° C until use.
Treatment
In patients showing obstructive jaundice due to a pancreatic head tumor, biliary drainage was achieved by endoscopic biliary drainage or percutaneous trans-hepatic cholangiodrainage before the initiation of chemotherapy.
Chemotherapy was continued until the disease progressed or the condition of patients deteriorated.
Gemcitabine monotherapy: gemcitabine was administered at a dose of 1,000 mg/m 2 intravenously over 30 minutes on days 1, 8, 15 of a 28-day cycle.
Gemcitabine plus cisplatin: patients were treated with gemcitabine at a dose of 800 mg/m 2 plus cisplatin at a dose of 10 mg/ body intravenously over 30 minutes on days 1, 8, 15 of a 28-day cycle.
Gemcitabine plus erlotinib: patients were treated with oral erlotinib 100 mg/day on days 1-28, plus gemcitabine at a dose of 1,000 mg/m 2 intravenously over 30 min on days 1, 8, 15 of a 28-day cycle.
S-1 monotherapy: S-1 was administered orally twice daily at a dose according to the body-surface area (BSA) (<1.25 m 2 , 80 mg/ day; ≥ 1.25 to <1.5 m 2 , 100 mg/day; ≥ 1.5 m 2 , 120 mg/day) on days 1-28 of a 42-day cycle.
Gemcitabine plus S-1: patients received gemcitabine at a dose of 1,000 mg/m 2 intravenously over 30 minutes on days 1, 8 plus S-1 orally twice daily at a dose according to the BSA (<1.25 m 2 , 60 mg/ day; ≥ 1.25 to <1.5 m 2 , 80 mg/day; ≥ 1.5 m 2 , 100 mg/day) on days 1-14 of a 21-day cycle.
In some patients, radiotherapy was targeted to the primary tumor and administered at a total radiation dose of 50.4 Gy with a daily fraction of 1.8 Gy 5 times/week.
The response evaluation criteria in solid tumors [22] were applied to assess the response to chemotherapy.
Endpoint
The primary endpoint was overall survival, measured from the first day of chemotherapy until the date of death for any cause or December 31, 2013.
Indirect Enzyme-Linked Immunosorbent Assay
Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay (ELISA) using Protein Detector ELISA Kit (Kirkegaard & Perry Laboratories, Gaithersburg, Md. USA). All serum samples were tested in duplicate.
Briefly, 96-well U-bottom microtiter plates (Greiner Bio-One GmbH, Frickenhausen, Germany) were coated with 100 μl of 1 μg/ ml full-length recombinant RPL29 (Abnova, Taipei, Taiwan) in phosphate-buffered saline (PBS) at room temperature for 1 h. Unbound antigen was removed, nonspecific binding sites were blocked by incubation with 1% bovine-serum albumin (BSA) in PBS, and the wells were incubated with 100 μl of human sera diluted 1: 100 in PBS with 1% of BSA for 1 h. Following incubation, the wells were incubated with horseradish peroxidase-labeled antihuman IgG diluted 1: 1,000 in PBS with 1% of BSA, and the reaction was visualized by adding 100 μl of ABTS peroxidase substrate solution buffer (Kirkegaard & Perry Laboratories, Gaithersburg, Md., USA). The optical densities at 405 nm were read with a Model 680 microplate reader (Bio-Rad Laboratories, Hercules, Calif.,
Parameter
Number of patients (%) CA 19-9 = Carbohydrate antigen 19-9; UICC = the International Union against Cancer; ULN = upper limit of normal. 167 USA). In order to avoid inter-plate variability, we used a positive serum, assigned it 2.33 OD 405 nm , and read the optical densities of all samples against this positive serum. Intra-assay variability was found to be 5.1%.
The cut-off of serum anti-RPL29 level was represented by the 95th percentile in 62 controls.
Statistical Analysis
Statistical analysis was performed using the IBM SPSS Statistics version 21 (IBM, Chicago, Ill., USA). Continuous variables were expressed as median (range). Differences in continuous variables were evaluated by the Mann-Whitney U-test between two independent samples and the Kruskal-Wallis test among 3 independent samples. Dichotomous variables were compared by the χ 2 -test. Univariate and multivariate Cox proportional hazard models were performed to identify prognostic factors, and results are presented as hazard ratios (HRs) along with their 95% confidence intervals (CIs). The variables, which showed p < 0.2 by univariate analysis, were included into the multivariate analysis. Cumulative survival curves were analyzed using the Kaplan-Meier method, and the differences in the curves were tested using the log-rank test. p values <0.05 (all two-sided) were considered significant.
Results
Characteristics of Study Population
Until December 31, 2013, ninety-eight (93%) patients died, and the overall MST was 8.7 months ( fig. 1 ) . MST was 15.1 months in 41 patients with locally advanced disease and 7.3 months in 64 patients with metastatic disease.
Treatment characteristics are shown in table 2 . Before the initiation of chemotherapy, biliary drainage was performed in 40 patients who had a pancreatic head tumor. Median time from the diagnosis of pancreatic cancer to the initiation of the first-line chemotherapy was 9 (range, 1-55) days and longer in 40 patients in need of biliary drainage [12 (3-55) days versus 8 (1-47) days, p = 0.034]. At the initiation of the first-line chemotherapy, 16 patients had serum CA 19-9 level less than 37 U/ml (upper limit of normal). Of 89 patients showing serum CA 19-9 level at the initiation of the first-line chemotherapy ≥ 37 U/ml, a decrease in serum CA 19-9 levels by at least 50% on day 56 was shown in 25 patients [2 patients with partial response (PR), 22 patients with stable disease (SD), and one patient with progressive disease (PD)]. One patient with complete response (CR) showed serum CA 19-9 level <37 U/ml at the initiation of the first-line chemotherapy.
Serum Anti-RPL29 Level
Serum anti-RPL29 levels at the initiation of the firstline chemotherapy are shown in figure 2 . Serum anti-RPL29 levels were higher in patients with unresectable 16 ( The cut-off value of serum anti-RPL29 level is 0.53 OD 405 nm . Anti-RPL29 = Anti-60S ribosomal protein L29 antibody; CA19-9 = carbohydrate antigen 19-9; PD = progressive disease. ( table 4 ) . Age, gender, platelet-lymphocyte ratio, serum C-reactive protein level, and modified Glasgow prognostic score were not sig- In 75 patients treated with gemcitabine alone as the first-line chemotherapy, univariate analysis identified serum anti-RPL29 level, abdominal or back pain, performance status, tumor location, tumor spread, and neutrophil-lymphocyte ratio as prognostic factors. In the multivariate analysis that included serum anti-RPL29 level, abdominal or back pain, performance status, tumor location, tumor spread, neutrophil-lymphocyte ratio, serum bilirubin level, and serum CA 19-9 level, we identified 
Discussion
Recently, glycosylation of IgG, which influences IgG effector function, has been reported to be associated with the prognosis of malignant tumors including pancreatic cancer [23, 24] . This indicates that serum IgG of cancer patients may contain some autoantibodies associated with the disease progression, and autologous tumor can become a target of anti-tumor immune response in vivo. Until now, many autoantibodies against autologous tumor-associated antigens (TAAs) have been reported. In pancreatic cancer, the presence of serum anti-MUC1 antibodies has been shown to be associated with the better prognosis [25] , but associations of serum antibodies to autologous TAAs with the prognosis have not been fully elucidated yet.
Ribosomes are essential components of the protein translation machinery, and are composed of more than 80 unique large and small ribosomal proteins. Some ribosomal proteins control cell proliferation, and autoantibodies to some ribosomal proteins may exist in human 171 sera and influence cell proliferation. Previously, autoantibodies to ribosomal protein LP0 (RPLP0), which exists in the cytoplasmic and on the surface of cells and takes part in the regulation of protein synthesis, have been revealed to exist in human sera of patients with head and neck cancer [26] and patients with breast cancer [27] . Anti-RPLP0 antibodies induce cell cycle arrest at sub-G1 phase and promote apoptosis [28] ; however, the associations of serum anti-RPLP0 antibodies with the prognosis of cancer patients have not revealed yet. In this study, the prognosis of patients with unresectable pancreatic cancer, who were mainly treated with gemcitabine alone or gemicitabine-based combination chemotherapy, did not differ from those reported previously [4] . And, performance status, tumor stage, and abdominal or back pain were identified as prognostic factors for unresectable pancreatic cancer. These results are consistent with those of the previous reports [7] [8] [9] . Thus, clinical features of patients with unresectable pancreatic cancer included into this study seem to be common. On the other hand, serum anti-RPL29 level, which was elevated in some patients with unresectable pancreatic cancer, was associated with their survival as an independent prognostic factor. Patients showing serum anti-RPL29 levels >cut-off seem to have longer survivals compared with the general patients with unresectable pancreatic cancer treated with gemcitabine based chemotherapy [4] . To our knowledge, this study is the first to focus on serum anti-RPL29 as a prognostic marker for unresectable pancreatic cancer. Serum anti-RPL29 level may be useful for predicting the prognosis of unresecatble pancreatic cancer.
Immune response to autologous tumor has been shown to improve the prognosis in vivo [29] . In peripheral blood from pancreatic cancer patients, circulating tumor cells are frequently detected [30] . So, spontaneous immune response to autologous pancreatic cancer cells may be induced. The expression of RPL29 is upregulated in various types of cancers including pancreatic cancer [12, [14] [15] [16] 18] . In this study, serum anti-RPL29 levels, which were elevated in 47% of the patients with unresectable pancreatic cancer compared with healthy volunteers, were associated with their survival. So, RPL29 may be an autologous TAA, and serum anti-RPL29 levels may reflect the grade of spontaneous immune response to autologous cancer cells. On the other hand, neutrophil-lymphocyte ratio, which reflects systemic inflammatory response [9] , was identified as a prognostic factor by the Anti-RPL29 = Anti-60S ribosomal protein L29 antibody; CA19-9 = carbohydrate antigen 19-9; CI = confidence interval; HR = hazard ratio; mGPS = modified Glasgow prognostic score. univariate analysis, but the multivariate analysis including serum anti-RPL29 level did not show the association of neutrophil-lymphocyte ratio with patients' survival. This may indicate that markers reflecting the grade of spontaneous immune response to autologous cancer cells rather than systemic inflammatory response are suitable for predicting the prognosis of unresectable pancreatic cancer.
This study indicates that, in patients treated with gemcitabine alone as the first-line chemotherapy, serum anti-RPL29 level is not associated with the best overall response, but those showing elevated serum anti-RPL29 levels have better prognosis. Thus, induction of immune response to RPL29 may be effective to suppress the disease progression. On the other hand, in this study, T cell response to RPL29 was not investigated. Hereafter, in order to develop RPL29-based immunotherapy, it will be necessary to investigate the association between T cell response to RPL29 and the prognosis in patients with unresectable pancreatic cancer.
In pancreatic cancer, Wnt/beta-catenin signaling, apoptosis signaling, and regulation of G1/S phase transition are core signaling pathways responsible for pancreatic tumorigenesis, and genetic alterations in these core signaling pathway are nearly universal [31] . RPL29 has been found to be one of the candidate targets of Wnt/ beta-catenin signaling [14] . Additionally, silencing of RPL29 upregulates the expression of p21, inhibitor of cell cycle progression through G1/S phase, and p53, inducer of apoptosis [19] . Thus, RPL29 may be a candidate target molecule for pancreatic cancer therapy although further studies are required.
This study had several limitations. First, this study was a retrospective, single-center study. Second, many patients were treated with gemcitabine alone as the first-line chemotherapy. Some were treated with gemcitabine plus cisplatin or gemcitabine plus erlotinib. But, none was treated with FOLFIRINOX. Hereafter, FOLFIRINOX are speculated to become the standard regimen for unresectable pancreatic cancer. In order to confirm our findings, a multicenter prospective validation study, registered with the UMIN Clinical Trials Registry (number: UMIN000011478), is under execution.
In conclusion, this study indicates that some patients with unresectable pancreatic cancer show elevated serum anti-RPL29 levels, and that serum anti-RPL29 levels are associated with the prognosis of unresectable pancreatic cancer, independent of performance status, tumor stage, and serum CA 19-9 level. Thus, serum anti-RPL29 level may be a novel candidate for a prognostic marker for unresectable pancreatic cancer, although further studies are required.
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